SEARCH:
Print

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, January 6, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 

1.

Details of the   person discharging managerial responsibilities/person closely associated  

a)

Name

Jean-Christophe May

2.

Reason for the   notification

a)

Position/status

 

Executive Vice   President and Chief Commercial Officer of Bavarian Nordic A/S

b)

Initial   notification/Amendment

Initial   notification

3.

Details of the   issuer, emission allowance market participant, auction platform, auctioneer   or auction monitor

a)

Name

Bavarian Nordic A/S

b)

LEI

2138006JCDVYIN6INP51

4.

Details of the   transaction(s): section to be repeated for (i) each type of instrument; (ii)   each type of transaction; (iii) each date; and (iv) each place where   transactions have been conducted

a)

Description of   the financial instrument, type of instrument
 
 

Identification   code

Warrants


 
  N/A

b)

Nature of the   transaction

Grant

c)

Price(s) and   volume(s)

Price(s)

Volume(s)

 

 

DKK 0.00

23,763

d)

Aggregated   information

-       Aggregated   volume

-       Price

 

23,763
  DKK 0.00

e)

Date of the   transaction

2020-01-06

f)

Place of the   transaction

Outside a trading   venue

 

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and has been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com

Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43 

Graham Morrell
Paddock Circle Advisors (US)
graham@paddockcircle.com
Tel: +1 781 686 9600

Company Announcement no. 02 / 2020

Published on January 06, 2020, 7:35 CET